VTVT - vTv Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

vTv Therapeutics Inc.

4170 Mendenhall Oaks Parkway
High Point, NC 27265
United States
336-841-0300
http://www.vtvtherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees52

Key Executives

NameTitlePayExercisedYear Born
Mr. Jeffrey B. KindlerExec. Chairman250kN/A1956
Mr. Stephen L. HolcombePres & CEO459.4kN/A1957
Mr. Rudy C. Howard CPA, B.A., CPAExec. VP & CFO357.24kN/A1958
Dr. Carmen Valcarce Ph.D.Chief Scientific Officer & Exec. VPN/AN/AN/A
Ms. Robin E. AbramsExec. VP & Gen. CounselN/AN/A1964
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Corporate Governance

vTv Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.